HK Stock Market Move | TYK MEDICINES-B (02410) surged over 6% in early trading, with significant narrowing of losses in the first half of the year. Commercialization of TY-9591 accelerates.

TYK MEDICINES-B (02410) rose over 6% in early trading, and as of this report, it has increased by 5.63%, reaching HKD 7.13, with a transaction volume of HKD 16.1464 million. In terms of news, Tongyuan Kang Pharmaceutical announced its interim results, reporting R&D expenses of HKD 94.943 million, up 7% year-on-year; administrative expenses of HKD 62.554 million, up 61.3% year-on-year; and a loss attributable to equity holders of the parent company of HKD 24.897 million, a reduction of 77.81% year-on-year. It is noteworthy that in July this year, Tongyuan Kang Pharmaceutical reached a collaboration agreement with Qilu Pharmaceutical, and both parties will work together to develop and produce the raw material drug TY-9591, as well as commercializing TY-9591 in mainland China. Meanwhile, Qilu Pharmaceutical will also make an equity investment in Tongyuan Kang Pharmaceutical. It is reported that the New Drug Application (NDA) for TY-9591 has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China in early 2026 and has been included in the priority review and approval process.